Decreased UACR Linked to Reduced Risk for Cardiovascular, Renal Events in T2D
Urinary albumin-to-creatinine ratio values are often used to guide treatment decisions as albuminuria is known to be a strong predictor of cardiovascular and renal events.
Diabetic Nephropathy
Albuminuria Reduction Greater With SGLT2 Inhibitor, ERA Combo
A move toward combination therapies is inevitable in the new paradigm for diabetic kidney disease management, according to the authors of an editorial.
Intensive Urate-Lowering May Protect Kidneys in Type 2 Diabetes
The effects of combined verinurad and febuxostat treatment were independent of blood pressure.
Albuminuria Down in Adults With Newly Diagnosed T2DM
Improvements seen in glycemic, blood pressure, lipid control within the population partly explain decrease in albuminuria
Finerenone Gets Priority Review for Diabetic Kidney Disease
The FDA has accepted for Priority Review the NDA for finerenone for chronic kidney disease in patients with type 2 diabetes.
Canagliflozin Beneficial Even for Advanced Kidney Disease
Canagliflozin slows progression of kidney disease in participants with eGFR <30 mL/min/1.73 m2 with no increase in AKI
Sotagliflozin Reduces Risk for Adverse CV Events in Diabetic Kidney Disease
Sotagliflozin might help patients with diabetes and chronic kidney disease who are hospitalized with heart failure avoid a readmission, study results suggest.
Nephropathy Progression in Type 1 Diabetes Linked to Depression
Whether successful treatment of depression reduces the risk for progression needs to be determined.
Finerenone NDA Submitted for Diabetic Kidney Disease
The NDA for finerenone is supported by data from the double-blind, placebo-controlled phase 3 FIDELIO-DKD trial.
Highlights From the New KDIGO Guideline on Diabetes and CKD
The new KDIGO guideline highlights specific management differences by CKD severity.
-
Loading...
-
Loading...
Next post in Chronic Kidney Disease (CKD)
